Oxford Drug Design awarded £1m PACE funding to progress uUTI treatment
As part of company’s tRNA synthetase development in oncology and infections Oxford Drug Design has been awarded £1m in funding to progress […]
Oxford Drug Design achieves further in vivo validation of novel approach against multiple tumours
Oxford Drug Design, the Oxford-based AI drug discovery company, has announced today additional in vivo validation for its first-in-class approach against cancer […]
Oxford Drug Design awarded share of £3m Cystic Fibrosis Collaborative Drug Discovery Programme
The cross-sector initiative provides funding and support to accelerate new treatments for lung infections in Cystic Fibrosis September 26th 2024, United Kingdom: […]